



Alexion Receives International Investor Award 2016 from the Greater Paris Investment Agency for Innovative Research and Science in Rare Diseases

FRANCE, Paris – July 7, 2016 – Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) has been honored with a 2016 International Investor Award from the Greater Paris Investment Agency (Paris-Ile de France Capitale Economique) for its significant investment and growth in Paris, France. Alexion first established its presence in France in 2005 and, in 2015, opened a new Research and Development Center in Paris – its first European research hub for rare and severe diseases. The state-of-the-art R&D Center aims to advance the understanding of devastating and rare diseases, in addition to facilitating the discovery of life-transforming therapies for patients suffering from these disorders.

“We are pleased to accept this award from the Greater Paris Investment Agency and proud to be one of the few companies researching and developing therapies to treat rare and ultra-rare diseases. Our R&D Center in Paris plays a critical role in helping to achieve our mission to transform the lives of patients globally who suffer from severe and rare disorders,” said Martin Mackay, Ph.D., Executive Vice President and Head of R&D at Alexion. “As a global R&D leader, it is critically important to have a center of excellence in R&D for rare diseases in Europe, and Paris is an attractive location, with its large pool of highly talented life-science professionals and long track record of scientific excellence. We collaborate with world-renowned researchers throughout France, many of whom played an instrumental role in the successful development of our transformational therapy, Soliris, and are supporting our ongoing development programs.”

The Greater Paris Investment Agency honors three companies annually with an International Investor Award based on their contribution to driving investment, employment and development in Paris and the region. “We are pleased to be honoring, this year, an innovative biotech company with an International Investor Award, acknowledging Alexion’s contribution to advancing research and science for patients with rare diseases where there is significant unmet medical need,” said Christian Nibourel, President of the Greater Paris Investment Agency (Paris-Ile de France Capitale Economique). “Life-sciences are an important sector for the Greater Paris area and we believe this research commitment showcases the continued growth of the industry in the region.”

Alexion’s R&D Center Paris, which is located at the campus of the Necker Hospital at the Imagine Institute, focuses on discovery research activities in the fields of cell and molecular biology, genomics, and immunogenicity. Alexion plans to pursue additional collaborations with other leading hospitals and research centers in France and throughout Europe.

Today, Alexion’s R&D team is advancing the broadest pipeline in the Company’s history. The R&D Center in Paris is a vital part of Alexion’s overall R&D operations, which also includes research facilities in the United States in Connecticut and the Greater Boston Area (Massachusetts). Alexion’s breakthrough medical innovation has been recognized worldwide; in 2009, Alexion was proud to receive the Prix Galien in France for its first product to market, Soliris, in the category of drugs for rare diseases.

For further information about the award, and the 2016 winners, please visit <http://www.greater-paris-investment-agency.com/>

About Alexion

Alexion is a biopharmaceutical company focused on serving patients with severe and rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition and has developed and markets a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. The treatment is currently approved in nearly 50 countries for the treatment of PNH and in nearly 40 countries for the treatment of aHUS. Alexion is evaluating other potential indications for the treatment in additional severe and ultra-rare disorders beyond PNH and aHUS, and is developing other highly innovative biotechnology product candidates, across multiple therapeutic areas. Further information about Alexion can be found at: <http://www.alexionpharma.fr> and <http://www.alexionpharma.eu/>

Media contact

Alexion Pharmaceuticals

Lauren Cettier, +41 (0)79 572 25 83

Director, Corporate Communications